| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | An E.coli-derived zebrafish Integrin-linked kinase recombinant protein (amino acids R9-K452) was used as the immunogen for the Zebrafish Integrin-linked kinase antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Zebrafish Integrin-linked kinase Antibody / ILK is an antibody targeting ILK, raised in Rabbit for protein detection and localization studies where these specifications are required.
Key elements and design rationale
- Target: ILK (reported localization: Cytoplasm).
- Antibody identity: Polyclonal (rabbit origin); Rabbit Ig.
- Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
- Format: Antigen affinity purified.
- Species reactivity: Zebrafish.
- Listed applications: WB (refer to on-page specifications for application-specific guidance).
Biological background
ILK / Integrin-linked kinase is a key player in the intricate network of proteins that make up the cell's cytoskeleton. It acts as a signaling hub, translating external signals from the extracellular environment into various cellular responses. One of the most fascinating aspects of Integrin-linked kinase is its ability to interact with integrins, a group of proteins that play a critical role in cell adhesion and migration. By forming complexes with integrins, Integrin-linked kinase helps to regulate processes such as cell proliferation, survival, and differentiation. Furthermore, it has been implicated in a wide range of diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. Researchers have found that dysregulation of Integrin-linked kinase can lead to abnormal cell growth and invasion, highlighting the importance of understanding this protein in both health and disease.
Research relevance and current trends
- Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
- Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
- Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.
Common research applications
- Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.
Notes for experimental interpretation
- Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
- Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
- Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
- Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.